The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

British Columbia has become a major hub of biotech innovation within the last decade or more, and the popular coastal city of Vancouver is the center of the life sciences sector in the province. In ...

The J.P. Morgan Healthcare Summit (JPM) serves as the world’s largest healthcare conference where healthcare professionals, scientists, and innovators meet with investors to set the agenda for the ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

Life science companies regularly forge mergers and acquisition (M&A) deals to eliminate competition or to expand a pipeline. Recently, there has been a spike in M&As, but analysts point towards ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...

Hemophilia is a rare, genetic disorder in which the blood does not clot enough to make bleeding slow down or stop. This is because patients with hemophilia do not have the normal amount of clotting ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

The biopharma industry has seen its fair share of clinical and financial failures. When biotechs face setbacks, their stock values plummet and they lack the funds to develop new medicines, restructure ...